Antibody-oligonucleotide conjugates

by cailynn on Mar 6th, 2025 07:54 AM

Antibody-oligonucleotide conjugates (AOCs) represent a cutting-edge approach in targeted therapy, combining the specificity of antibodies with the therapeutic potential of oligonucleotides. These conjugates are designed to deliver genetic material directly to diseased cells, enhancing precision and reducing off-target effects. AOCs hold promise in treating cancers, genetic disorders, and infectious diseases by enabling targeted gene silencing or modulation. Their development is advancing rapidly, offering new avenues for personalized medicine and improved treatment outcomes.